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Background
The interaction of gp120 with CD4 is the first step of HIV
cycle. It is the pivotal event allowing the entry of HIV into
CD4+ cells. gp120 is the main target for neutralizing anti-
bodies (nAb) but most of its accessible epitopes are highly
variable and thus, HIV can bypass these nAbs.
Single domain antibodies (sdAb) derived from llama
antibodies bind their antigen without requiring variable
domains pairing. They are able to bind unconventional
epitopes, like those present in protein cavities. Their small
size (13 kDa) allows them to accede to very narrow space,
such as the space between virus and cell membranes dur-
ing infection. SdAbs are highly stable, easy to clone and
produce in large amounts.
Methods
Using trimeric gp140, free or bound to a CD4 mimic, as
immunogens in llamas, we selected a panel of broadly
neutralizing single-domain antibodies that bind either to
the CD4 or to the co-receptor binding sites (CD4BS and
CoRBS, respectively).
Results
When analyzed as monomers or as homo- or hetero-mul-
timers, the best sdAb candidates could not only neutralize
viruses carrying subtype B envelopes, corresponding to the
Env molecule used for immunization and selection, but
were also efficient in neutralizing a broad panel of envel-
opes from subtypes A, C, G and CRF01_AE. Interestingly,
sdAb multimers exhibited a broader spectrum of neutra-
lizing activity than the parental sdAb monomers.
Conclusion
The extreme stability and high recombinant production
yield combined to their broad neutralization capacity
make these sdAbs new potential microbicide candidates
for HIV-1 transmission prevention.
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